Aerie Pharmaceuticals Inc (AERI) CFO Sells $2,076,587.04 in Stock

Aerie Pharmaceuticals Inc (NASDAQ:AERI) CFO Richard J. Rubino sold 34,512 shares of the stock in a transaction on Thursday, September 13th. The shares were sold at an average price of $60.17, for a total value of $2,076,587.04. Following the sale, the chief financial officer now owns 383,738 shares of the company’s stock, valued at approximately $23,089,515.46. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.

Shares of AERI stock opened at $59.15 on Monday. The firm has a market capitalization of $2.64 billion, a P/E ratio of -17.55 and a beta of 0.77. The company has a quick ratio of 10.07, a current ratio of 10.27 and a debt-to-equity ratio of 0.64. Aerie Pharmaceuticals Inc has a 1 year low of $47.05 and a 1 year high of $74.75.

Aerie Pharmaceuticals (NASDAQ:AERI) last issued its earnings results on Wednesday, August 8th. The company reported ($1.14) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.98) by ($0.16). The company had revenue of $2.42 million during the quarter, compared to the consensus estimate of $1.16 million. analysts forecast that Aerie Pharmaceuticals Inc will post -4.51 EPS for the current fiscal year.

Several analysts have recently commented on the company. BidaskClub upgraded Aerie Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 23rd. Stifel Nicolaus increased their price objective on Aerie Pharmaceuticals from $80.00 to $87.00 and gave the company a “buy” rating in a report on Tuesday, September 11th. Needham & Company LLC set a $86.00 price objective on Aerie Pharmaceuticals and gave the company a “buy” rating in a report on Friday, July 13th. Cowen increased their price objective on Aerie Pharmaceuticals from $100.00 to $105.00 and gave the company a “buy” rating in a report on Thursday, August 9th. Finally, Canaccord Genuity set a $86.00 target price on Aerie Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday, June 5th. One analyst has rated the stock with a sell rating, one has given a hold rating and eleven have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $83.10.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Metropolitan Life Insurance Co. NY raised its stake in shares of Aerie Pharmaceuticals by 8.2% during the 2nd quarter. Metropolitan Life Insurance Co. NY now owns 11,576 shares of the company’s stock valued at $782,000 after buying an additional 877 shares during the last quarter. Amalgamated Bank raised its stake in shares of Aerie Pharmaceuticals by 20.0% during the 2nd quarter. Amalgamated Bank now owns 5,441 shares of the company’s stock valued at $368,000 after buying an additional 906 shares during the last quarter. Xact Kapitalforvaltning AB raised its stake in shares of Aerie Pharmaceuticals by 21.0% during the 2nd quarter. Xact Kapitalforvaltning AB now owns 5,751 shares of the company’s stock valued at $388,000 after buying an additional 1,000 shares during the last quarter. MetLife Investment Advisors LLC raised its stake in shares of Aerie Pharmaceuticals by 7.0% during the 2nd quarter. MetLife Investment Advisors LLC now owns 16,392 shares of the company’s stock valued at $1,107,000 after buying an additional 1,066 shares during the last quarter. Finally, Summit Trail Advisors LLC raised its stake in shares of Aerie Pharmaceuticals by 12.1% during the 1st quarter. Summit Trail Advisors LLC now owns 11,922 shares of the company’s stock valued at $440,000 after buying an additional 1,283 shares during the last quarter. Institutional investors and hedge funds own 96.00% of the company’s stock.

About Aerie Pharmaceuticals

Aerie Pharmaceuticals, Inc, an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases. Its lead product is Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.

Featured Story: Understanding Price to Earnings Ratio (PE)

Insider Buying and Selling by Quarter for Aerie Pharmaceuticals (NASDAQ:AERI)

Receive News & Ratings for Aerie Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply